Seroxat USERS Duckett funding bid - all other brands excluded

Seroxat USERS Ducket funding bid - all other brands excluded


source -

Disability Research Network e-Newsletter: Northern England Issue 1: April 2007





News from the Research Institute for Health and Social Change, Manchester Metropolitan University (http://www.rihsc.mmu.ac.uk/)



extract -


Research idea from Paul Duckett (p.duckett@mmu.ac.uk)



I am presently working with the Seroxat User Group to develop a funding bid (details below). Interest from other disability studies researcher welcomed: The Seroxat User Group is a UK patients group which provides support and advice to people who use or have used Seroxat (a prescription drug anti-depressant). Seroxat is commonly prescribed for people who have been given the diagnostic label of depression, anxiety and sexual dysfunction. In recent years, it has been shown that a significant number of people who have taken Seroxat have experienced severe problems in their attempts to withdraw from the drug and, whilst taking the drug, problems with suicidal and homicidal ideations. GlaxoSmithKline (GSK) are presently subject to a number of class action law suits in the UK, USA and elsewhere in relation to the company's alleged non-disclosure and distortion of the results of their clinical research trials on the efficacy and safety of Seroxat.The Seroxat User Group are a not-for-profit organisation that has so far relied on individual donations (surviving for four years on only ?800). In spite of the lack of funding, the Group has continued to operate a website resource for people concerned about the drug and have been lobbying government to ensure public safety is not being jeopardised in relation to the commercial activities of GSK.







This proposed research, being developed in consultation with the Seroxat User Group (SUG), will:



++ engage in a piece of participatory action research with SUG to set up



++ and



evaluate four self-help support groups, operated via general practitioner surgeries.



++ Research the relationship GSK following the attempts of SUG to file



++ class action lawsuits against

GSK.

If you are interested in exploring this research idea please contact Paul Duckett directly



read on here - http://www.breakthrough-uk.co.uk/OneStopCMS/Core/CrawlerResourceServer.aspx?resource=376D38AE-B971-4081-AB89-579F8C6857C4&mode=link&guid=51f63a9174a340298bec993159ae0da5